Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2375]

Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor...

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

$Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )$

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline...

Dr Lorenz Trümper - Georg August University, Göttingen, Germany

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )

AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed...

Prof Marion Subklewe - University of Munich, Munich, Germany

$AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )$

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for...

Dr Tait Shanafelt - Standford University, Stanford, USA

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )

Resistance mechanisms to venetoclax in patients with progressive CLL

Dr Piers Blombery - University of Melbourne, Melbourne, Australia

Resistance mechanisms to venetoclax in patients with progressive CLL ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy

Dr Alok Khorana - Cleveland Clinic, Cleveland, USA

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy ( Dr Alok Khorana - Cleveland Clinic, Cleveland, USA )

Ibrutinib-based therapy superior for younger patients with previously untreated...

Dr Tait Shanafelt - Stanford University, Stanford, USA

Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care ( Dr Tait Shanafelt - Stanford University, Stanford, USA )

Daratumumab found to increase PFS in patients with transplant-ineligible newly...

Prof Thierry Facon - Hôpital Claude Huriez, Lille, France

Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )

Multiple myeloma highlights and more from ASH 2018

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Multiple myeloma highlights and more from ASH 2018 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

Results of the Beat AML umbrella study for previously untreated acute myeloid...

Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA

Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )

Myeloma XI study: Quadruplet regimen for transplant eligible patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Myeloma XI study: Quadruplet regimen for transplant eligible patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Developments in CAR T treatments for adult patients

Dr David Miklos - Stanford University, Palo Alto, USA

Developments in CAR T treatments for adult patients ( Dr David Miklos - Stanford University, Palo Alto, USA )

More from ecancer